cy 208-243 has been researched along with Parkinson Disease, Secondary in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 8 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bédard, PJ; Di Paolo, T; Gagnon, C; Gomez-Mancilla, B | 1 |
| Guillén, J; Laguna, J; Luquin, MR; Martínez-Lage, JM; Martínez-Vila, E | 1 |
| Fukuda, T; Nomoto, M | 1 |
| Bédard, PJ; Boucher, R; Di Paolo, T; Gagnon, C; Gomez-Mancilla, B; Markstein, R | 1 |
| Bédard, PJ; Di Paolo, T; Gagnon, C; Gomez-Mancilla, B; Markstein, R | 1 |
| Bedard, PJ; Blanchet, P; Chen, JS; Doucet, JP; Grondin, R; Hope, BT; Iadarola, MJ; Jasmin, BJ; Nakabeppu, Y; Nestler, EJ; Robertson, GS; St-Jean, M; Wigle, N | 1 |
| Bédard, PJ; Boucher, R; Gomez-Mancilla, B | 1 |
| Bédard, PJ; Gomez-Mancilla, B | 1 |
| Agid, Y; Bonnet, AM; Jenner, PG; Lataste, X; Markstein, R; Marsden, CD; Pourcher, E; Quinn, NP; Temlett, JA | 1 |
| Chong, PN; Jenner, P; Marsden, CD; Oertel, WH; Temlett, JA | 1 |
10 other study(ies) available for cy 208-243 and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Behavior, Animal; Brain Chemistry; Dopamine; Dopamine Agents; Dopamine D2 Receptor Antagonists; Female; GTP-Binding Proteins; Indoles; Macaca fascicularis; Neostriatum; Ovariectomy; Parkinson Disease, Secondary; Phenanthridines; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, GABA-A | 1993 |
Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys.
Topics: Animals; Benzazepines; Dopamine Agents; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Female; Indoles; Macaca fascicularis; Male; Motor Activity; MPTP Poisoning; Oxazines; Parkinson Disease, Secondary; Phenanthridines; Receptors, Dopamine D1; Receptors, Dopamine D2; Sulpiride | 1994 |
The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzazepines; Callithrix; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Female; Indoles; Male; Motor Activity; Parkinson Disease, Secondary; Phenanthridines; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1993 |
Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Bromocriptine; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Homovanillic Acid; Indoles; Locomotion; Macaca fascicularis; Motor Skills; Neurologic Examination; Parkinson Disease, Secondary; Phenanthridines; Psychomotor Performance; Receptors, Dopamine; Receptors, Dopamine D1 | 1993 |
Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors.
Topics: Animals; Autoradiography; Behavior, Animal; Brain Chemistry; Bromocriptine; Dopamine Agents; Dopamine Agonists; Female; Indoles; Macaca fascicularis; MPTP Poisoning; Neostriatum; Ovariectomy; Parkinson Disease, Secondary; Phenanthridines; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1995 |
Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
Topics: Animals; Bacterial Proteins; Base Sequence; Benzazepines; Blotting, Western; Cabergoline; Corpus Striatum; Denervation; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Ergolines; Female; Gene Expression Regulation; Genes, fos; Haloperidol; Indoles; Macaca fascicularis; Male; Molecular Weight; MPTP Poisoning; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Phenanthridines; Polymerase Chain Reaction; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Receptors, Dopamine D1; RNA, Messenger; Species Specificity; Time Factors; Transcription Factors | 1996 |
Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electromyography; Ergolines; Female; Indoles; Injections, Subcutaneous; Macaca fascicularis; Parkinson Disease, Secondary; Phenanthridines; Quinpirole; Tremor | 1992 |
Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys.
Topics: Animals; Antiparkinson Agents; Dopamine Agents; Female; Indoles; Macaca fascicularis; Motor Activity; MPTP Poisoning; Oxazines; Parkinson Disease, Secondary; Phenanthridines; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1992 |
Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Analgesics; Animals; Callitrichinae; Dopamine Agents; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Phenanthridines; Pyridines | 1989 |
The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Callitrichinae; Dopamine Antagonists; Dose-Response Relationship, Drug; Indoles; Motor Activity; Parkinson Disease, Secondary; Phenanthridines; Pyridines; Receptors, Dopamine; Receptors, Dopamine D1; Sulpiride | 1988 |